(Q24644683)

English

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers

scientific article

In more languages

Statements

scholarly article

0 references

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers (English)

0 references

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Nancy L Lewis

1

0 references

Lionel D Lewis

2

0 references

Joseph P Eder

3

0 references

Nandi J Reddy

4

0 references

Feng Guo

5

0 references

Kristen J Pierce

6

0 references

Anthony J Olszanski

7

0 references

Roger B Cohen

8

0 references

language of work or name

0 references

publication date

1 November 2009

0 references

Journal of Clinical Oncology

0 references

27

0 references

31

0 references

5262-9

0 references

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

7 April 2017

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

7 April 2017

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

7 April 2017

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

27 September 2017

PDGF receptors as targets in tumor treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

27 September 2017

The platelet-derived growth factor receptor as a therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

27 September 2017

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

27 September 2017

STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

27 September 2017

PDGF receptors as cancer drug targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

27 September 2017

Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

27 September 2017

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

28 November 2018

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773478

28 November 2018

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

1 reference

https://pubmed.ncbi.nlm.nih.gov/19738123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19738123

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.21.8487

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_ymkaj7qspzgpjocqkdge66wpe4

1 reference

https://api.fatcat.wiki/v0/release/ymkaj7qspzgpjocqkdge66wpe4

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24644683&oldid=1836411762"